市場調查報告書
商品編碼
1433401
全球瞳孔計市場 2023-2030Global Pupillometer Market 2023-2030 |
預計在預測期內(2023-2030年),全球瞳孔計市場將以 6.9%的CAGR成長。該市場的成長歸因於全球醫療保健需求的不斷成長。在醫療保健領域,對可靠、高效的診斷工具的需求不斷成長,特別是在眼科、神經病學和重症監護等領域。瞳孔計對於診斷神經系統疾病、腦外傷和監測重症監護患者非常重要。例如,2020年 8月,Topcon Healthcare 推出了新型 Aladdin-M 儀器。 Aladdin-M 整合了角膜地形圖、瞳孔測量和光學生物測量,能可靠地評估角膜曲率、瞳孔動態和眼軸長度指標。
全球瞳孔計市場依類型、應用和最終用戶進行細分。根據類型,市場分為數位和視訊。根據應用,市場細分為眼科、神經科、腫瘤科等。此外,根據最終用戶,市場細分為醫院、眼科診所等。眼科子類別預計將佔據應用領域的很大一部分市場佔有率。這種成長可歸因於對屈光手術和白內障手術中精確測量和精心規劃的要求所驅動的眼科手術的精確性需求。這導致人們對 SeeNa 等系統越來越感興趣,這些系統可以幫助外科醫生實現最佳的手術結果。例如,2023年10月,博士倫公司推出了針對屈光性白內障患者的SeeNa光學生物測量和地形圖系統。
在這些應用中,神經學細分市場預計將在全球瞳孔計市場中佔據相當大的佔有率。細分生長歸因於神經系統疾病的增加。神經系統疾病和創傷性腦損傷的盛行率不斷上升,需要利用瞳孔計等精確診斷設備來進行及時檢查和治療。例如,2021年2月,NeurOptics 推出了瞳孔測量教育研討會平台,其中包括一系列以產品和臨床為重點的演示,展示了瞳孔測量和神經瞳孔指數(NPi)在評估和篩檢高風險患者中的重要作用的神經損傷。
全球瞳孔計市場根據地理位置進一步細分,包括北美(美國和加拿大)、歐洲(英國、義大利、西班牙、德國、法國和歐洲其他地區)、亞太地區(印度、中國、日本、韓國、亞洲其他地區)以及世界其他地區(中東和非洲以及拉丁美洲)。其中,亞太地區預計將在全球市場中佔據顯著佔有率,因為該地區的瞳孔計透過一系列網站和供應商的可用性不斷增加,預計將推動市場擴張。
在所有地區中,北美地區預計在預測期內將以相當大的CAGR成長。區域成長歸因於該地區不斷成長的臨床需求。揭示放射學指標與神經系統疾病之間潛在關聯的資料強調了精確診斷方法的重要性。瞳孔計可以獨立量化瞳孔反應性,在 IPH 和缺血性中風等疾病的神經學檢查中越來越有用。根據美國國立衛生研究院(gov.)2022年 12月的研究,在 74 張 CT 影像的 53 名患者中,49.1%為女性,中位年齡為 67 歲。與缺血性中風患者相比,IPH 患者的 MLS-SP 和 PGS 較高,測量值分別為 6.2 毫米與 4.0 毫米以及 5.6 毫米與 3.4 毫米。研究發現瞳孔反應性和放射學位移標記之間沒有顯著關聯,但在 IPH 和缺血性中風隊列中發現 MLS-SP 和 Diff NPi 之間存在潛在關係。這表明中線移位和不對稱瞳孔反應性之間的關聯在 IPH 和缺血性中風之間有所不同,強調需要進行額外的前瞻性研究。
服務於瞳孔計市場的主要公司包括HAMAMATSU Group、HEINE Optotechnik GmbH & Co. KG、Johnson & Johnson Vision Care, Inc.、KARL STORZ、Konan Medical USA Inc.等。市場參與者透過各種策略(包括併購、夥伴關係、合作、融資和新產品發布),為市場成長做出了巨大貢獻,以保持市場競爭力。例如,2021年7月,NeurOptics在美國推出了NPi-300瞳孔計。 NPi-300 瞳孔計是一款用於成人和兒童患者神經系統檢查的多功能工具,涵蓋廣泛的診斷,例如創傷性腦損傷、中風、癲癇和其他醫療狀況。
Global Pupillometer Market Size, Share & Trends Analysis Report by Type (Digital, and Video), by Application (Ophthalmology, Neurology, Oncology, and Others) and by End User (Hospitals, Eye Clinics, and Others), Forecast Period (2023-2030)
The global pupillometer market is anticipated to grow at a CAGR of 6.9% during the forecast period (2023-2030). The market's growth is attributed to the growing demand in healthcare across the globe. In healthcare, it contains an increasing demand for reliable and efficient diagnostic tools, particularly in sectors such as ophthalmology, neurology, and critical care. The pupillometers are essential in diagnosing neurological diseases, brain traumas, and monitoring patients in critical care situations. For instance, in Augut 2020, Topcon Healthcare launched its new Aladdin-M instrument. Aladdin-M integrates corneal topography, pupillometry, and optical biometry to assess corneal curvature, pupil dynamics, and axial length metrics reliably.
The global pupillometer market is segmented on the type, application, and end user. Based on the type, the market is sub-segmented into digital, and video. Based on the application, the market is sub-segmented into ophthalmology, neurology, oncology, and others. Furthermore, on the basis of end user, the market is sub-segmented into hospitals, eye clinics, and others. The ophthalmology subcategory is expected to capture a significant portion of the market share within the application segment. The growth can be attributed to the demand for precision in eye surgeries is driven by the requirement for accurate measurements and meticulous planning in refractive surgeries and cataract procedures. This has led to an increased interest in systems such as, SeeNa, that aid surgeons in achieving the optimal surgical outcomes possible. For instance, in October 2023, Bausch + Lomb Corp. launched the SeeNa optical biometry and topography system for refractive cataract patients.
Among the application, the neurology sub-segment is expected to hold a considerable share of the global Pupillometer market. The segmental growth is attributed to the increasing neurological disorders. The rising prevalence of neurological conditions and traumatic brain injuries needs for the utilization of precise diagnostic equipment such as pupillometers to perform prompt examinations and therapies. For instane, in February 2021, NeurOptics launched Pupillometry Education Symposiums platform, that includes a series of both product and clinical-focused presentations that demonstrate the essential role pupillometry and the neurological pupil index (NPi) play in the assessment and screening of patients at risk of neurological injury.
The global pupillometer market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the increasing availability of pupillometers in the region via a range of websites and vendors is projected to drive market expansion.
Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the increasing clinical demand across the region. The data revealing potential associations between radiographic indicators and neurological disorders underscore the importance of precise diagnosis methods. Pupillometers, that can independently quantify pupil responsiveness, have been increasingly useful in neurological examinations for disorders such as IPH and ischemic stroke. According to the National Institute of health (gov.) in December 2022, as per the study among the 53 patients with 74 CT images, 49.1% were female, with a median age of 67 years. The patients with IPH showed greater MLS-SP and PGS compared to patients with ischemic stroke, with measurements of 6.2 mm versus 4.0 mm and 5.6 mm versus 3.4 mm, respectively. The study found no significant association between pupil reactivity and radiographic shift markers, but potential relationships were found between MLS-SP and Diff NPi in the IPH and ischemic stroke cohorts. This suggests that the connection between midline shift and asymmetric pupil reactivity varies between IPH and ischemic stroke, emphasizing the need for additional prospective research.
The major companies serving the pupillometer market includes HAMAMATSU Group, HEINE Optotechnik GmbH & Co. KG, Johnson & Johnson Vision Care, Inc., KARL STORZ, Konan Medical USA Inc. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2021,NeurOptics, launched NPi-300 Pupillometer in the US. The NPi-300 Pupillometer is a versatile tool for neurological examination in both adults and pediatric patients, covering a wide range of diagnoses such as traumatic brain injury, stroke, seizure, and other medical conditions.